Darifenacin or darifenacin hydrobromide

HDAC6 Inhibitor is a selective and potent inhibitor of HDAC6 (IC|50|= 0.002 nM, as compared with HDAC1 (IC|50|= 271 nM), HDAC2 (IC|50|= 252 nM), HDAC3 (IC|50|= 0.42 nM), HDAC8 (IC|50|= 6851 nM), and HDAC10 (IC|50|= 90.7 nM). HDAC6 Inhibitor also

HDAC6 Inhibitor is a selective and potent inhibitor of HDAC6 (IC|50|= 0.002 nM, as compared with HDAC1 (IC|50|= 271 nM), HDAC2 (IC|50|= 252 nM), HDAC3 (IC|50|= 0.42 nM), HDAC8 (IC|50|= 6851 nM), and HDAC10 (IC|50|= 90.7 nM). HDAC6 Inhibitor also

HDAC6 Inhibitor is a selective and potent inhibitor of HDAC6 (IC|50|= 0.002 nM, as compared with HDAC1 (IC|50|= 271 nM), HDAC2 (IC|50|= 252 nM), HDAC3 (IC|50|= 0.42 nM), HDAC8 (IC|50|= 6851 nM), and HDAC10 (IC|50|= 90.7 nM). HDAC6 Inhibitor also

HDAC6 Inhibitor is a selective and potent inhibitor of HDAC6 (IC|50|= 0.002 nM, as compared with HDAC1 (IC|50|= 271 nM), HDAC2 (IC|50|= 252 nM), HDAC3 (IC|50|= 0.42 nM), HDAC8 (IC|50|= 6851 nM), and HDAC10 (IC|50|= 90.7 nM). HDAC6 Inhibitor also

HDAC6 Inhibitor is a selective and potent inhibitor of HDAC6 (IC|50|= 0.002 nM, as compared with HDAC1 (IC|50|= 271 nM), HDAC2 (IC|50|= 252 nM), HDAC3 (IC|50|= 0.42 nM), HDAC8 (IC|50|= 6851 nM), and HDAC10 (IC|50|= 90.7 nM). HDAC6 Inhibitor also

A reversible inhibitor of Lp-PLA2 (IC₅₀ = 0.25 nM) that produces sustained inhibition of plasma Lp-PLA2 activity in humans.

A reversible inhibitor of Lp-PLA2 (IC₅₀ = 0.25 nM) that produces sustained inhibition of plasma Lp-PLA2 activity in humans.

A reversible inhibitor of Lp-PLA2 (IC₅₀ = 0.25 nM) that produces sustained inhibition of plasma Lp-PLA2 activity in humans.

A reversible inhibitor of Lp-PLA2 (IC₅₀ = 0.25 nM) that produces sustained inhibition of plasma Lp-PLA2 activity in humans.

Darbufelone is a dual inhibitor of cellular PGF 2α and LTB 4 production. Darbufelone potently inhibits PGHS-2 ( IC 50 = 0.19 μM) but is much less potent with PGHS-1 ( IC 50 =20 μM).In VitroDarbufelone is a noncompetitive inhibitor of PGHS-2 (K i

A TZD that increases the sensitivity of cells to insulin, stimulating insulin-induced PI3K activity at submicromolar concentrations increases insulin effectiveness in obese NIDDM subjects promotes adipocyte differentiation by up-regulating the

A TZD that increases the sensitivity of cells to insulin, stimulating insulin-induced PI3K activity at submicromolar concentrations increases insulin effectiveness in obese NIDDM subjects promotes adipocyte differentiation by up-regulating the